Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis

Kui-Ying Jiang; Li-Li Qi; Xin-Bo Liu; Yong Wang; Ling Wang

doi:10.3389/fonc.2022.1073932

Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis

Front Oncol. 2023 Jan 11:12:1073932. doi: 10.3389/fonc.2022.1073932. eCollection 2022.

Authors

Kui-Ying Jiang¹, Li-Li Qi^{1

2}, Xin-Bo Liu³, Yong Wang⁴, Ling Wang¹

Affiliations

¹ Department of Orthopedic Oncology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
² Experimental Teaching Center, Hebei Medical University, Shijiazhuang, Hebei, China.
³ Department of thoracic surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
⁴ Department of Academic Research, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Abstract

Background: Siglec-15 is expressed in a variety of cancers. However, the role of Siglec-15 in the prognosis of cancer patients remains controversial. Therefore, we conducted a meta-analysis to clarify the potential prognostic value of Siglec-15 in solid tumors.

Methods: The PubMed, Web of Science, Embase and CNKI databases were comprehensively searched to identify studies assessing the effect of Siglec-15 on the survival of cancer patients. Hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS), progression-free survival (PFS) and disease-specific survival (DSS) from individual studies were evaluated.

Results: The data from 13 observational studies consisting of 1376 patients were summarized. Elevated baseline Siglec-15 expression was significantly correlated with poor OS (pooled HR = 1.28, 95% CI: 1.05-1.56; P = 0.013). However, high Siglec-15 expression predicted a significantly better DSS (pooled HR = 0.73 (95% CI: 0.57-0.94; P = 0.015) but not PFS (pooled HR = 1.49, 95% CI: 0.46-4.87; P=0.510). In addition, high Siglec-15 expression was not associated with PD-L1 (OR=0.64, 95% CI: 0.42-0.95; P = 0.028). High Siglec-15 expression was associated with male sex (OR = 1.39, 95% CI: 1.05-1.84; P = 0.022), larger tumor size (OR = 1.896, 95% CI: 1.26-2.9; P = 0.002), and advanced tumor-node-metastasis (TNM) stage (OR = 1.84; 95% CI: 1.19-2.84; P =0.006) in solid tumors.

Conclusions: This updated study suggested the expression of Siglec-15 is significantly associated with poor outcomes in human solid tumors, but further studies are needed to determine the prognostic value of Siglec-15 in solid tumors.

Keywords: Siglec-15; immune; meta-analysis; prognostic biomarker; solid tumor.

Publication types

Systematic Review

Grants and funding

This work was supported by several grants from National Natural Science Foundation of China (82173210), Hebei Natural Science Foundation (H2021206176) and outstanding medical talents project supported by Hebei Province in 2022.